Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New breast cancer study findings reported from V. Ludovini and co-authors
June 19th, 2008
According to a study from Perugia, Italy, "We explored the correlation between serum human epidermal growth factor receptor- 2 ( HER2) extracellular domain ( ECD) and tissue HER2 status, their relationship with clinicopathological parameters and their impact on disease- free survival ( DFS) and overall survival in early breast cancer patients. This prospective trial included patients with stage I - III breast cancer." "Serum HER2 ECD levels were measured by two enzyme- linked immunosorbent assays before surgical treatment. Tissue HER2 status was analyzed by immunohistochemistry ( IHC) in all tumors; FISH assay was utilized in HER2 2+ tumors by IHC. From May 2000 to July...
Source: Women's Health Weekly (2008-06-19)
|
